Meluzio Michael Vincent's Form 4 filing
Cue Biopharma, Inc.CUE · filed Aug 17, 2026
- Accession no.
- 0002138368-26-000007
- Filed
- Aug 17, 2026, 6:19 PM ET
- Trade date
- Aug 13, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $169.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meluzio Michael VincentCIK 0002138368 | Officer (VP, Prin. Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Common Stock | MOption exerciseAcquired | +13,647 | $0.00 | $0 | 54,589 | Direct | |
| Aug 13, 2026 | Common Stock | SSaleDisposed | −1,519 | $29.37F2 | −$44,613.03 | 53,070 | Direct | |
| Aug 13, 2026 | Common Stock | SSaleDisposed | −4,106 | $30.35F3 | −$124,617.1 | 48,964 | Direct | |
| Aug 13, 2026 | Common Stock | SSaleDisposed | −3 | $31.13 | −$93.39 | 48,961 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Common Stock | MOption exerciseDisposed | −13,647 | $0.00 | $0 | 27,295 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.97 to $29.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $29.99 to $30.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades.
Referenced by the price of 1 transaction in Table I.